Intelligent Bio Solutions INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Intelligent Bio Solutions Inc. Director Steven Boyages was granted 5,000 restricted common shares, subject to time-based vesting.
NASDAQ
Intelligent Bio Solutions Inc. director Nicola Fraser was granted 5,000 restricted common shares, subject to a 12-month vesting period.
NASDAQ
Intelligent Bio Solutions CFO Spiro Sakiris received 30,500 restricted common stock shares under the 2019 Long Term Incentive Plan, subject to vesting conditions.
NASDAQ
Intelligent Bio Solutions Inc. director Jonathan Scott Hurd was granted 5,000 restricted shares of common stock, subject to a 12-month vesting period.
NASDAQ
Intelligent Bio Solutions Inc. director Jason Isenberg was granted 5,000 restricted common shares, subject to a 12-month vesting period.
NASDAQ
Intelligent Bio Solutions Inc. CEO Harry Simeonidis received 30,500 restricted common shares under the company's 2019 Long Term Incentive Plan, subject to vesting conditions.
NASDAQ
Spiro Kevin Sakiris, CFO of Intelligent Bio Solutions Inc., received 34,500 shares of common stock and corrected previous reporting errors regarding his holdings.
NASDAQ
Harry Simeonidis, CEO of Intelligent Bio Solutions Inc., reports the acquisition of 40,000 shares of common stock on September 25, 2024, as part of a long-term incentive plan.
NASDAQ
Spiro Kevin Sakiris, CFO of Intelligent Bio Solutions Inc., received 34,500 shares of common stock and corrected clerical errors in previous filings regarding his holdings.
NASDAQ
Spiro Kevin Sakiris, CFO of Intelligent Bio Solutions, reports acquisition of common stock and exercise of warrants.